VMAC panel split on Proheart 6 question - DVM
  • SEARCH:
News Center
DVM Featuring Information from:

ADVERTISEMENT

VMAC panel split on Proheart 6 question
CVM to review data presented, including large-scale epidemiologic study.

DVM360 MAGAZINE


"We are very confident in the safety and efficacy of ProHeart 6, and will continue to provide our relevant data in the event the FDA continues reviewing the product," Novak adds.

Adverse events reported to FDA totaled 5,669, which was reported widely by the national news media. Adverse events resulting in death were reported at 485 before the recall. FDA applies an algorithm to assign probability scores to determine the probability that the drug was the probable reason for the adverse event.

Fort Dodge believes that its data of approximately three unfiltered reports for each 10,000 doses sold and independent data of four reports per 10,000 doses administered is an accurate reflection on what was happening in the field.

The VMAC panel included: Drs. Arthur Craigmill, Susanne Aref, Corrie Brown, Mr. Gregory Jaffe, Jack Sherman, Katrina L. Mealey, John J. McGlone, Lisa Nolan, Mark Papich, Richard A. Sams, Charles L. Bennett, Michael I. Luster, John R. Glisson, Sam Groseclose, Tom Nelson, Michael R. Peterson, M. Gatz Riddell and Lauren A. Trepanier.


ADVERTISEMENT

Source: DVM360 MAGAZINE,
Click here